Skip to main content
New Year’s Sale — Build a balanced news diet with 40% off Vantage
Published loading...Updated

Promising Dementia Treatment Trial: Coya Therapeutics Completes Key FTD Study Enrollment with Zero Safety Issues

Summary by stocktitan.net
Biotech firm Coya enrolls 9 patients in Frontotemporal Dementia treatment study combining IL-2 and CTLA4-Ig. Following positive interim data, final results expected Q4 2025.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.Cross Cancel Icon

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news in on Monday, September 29, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal